|
KMID : 1036920240290010003
|
|
Annals of Pediatric Endocrinology & Metabolism
2024 Volume.29 No. 1 p.3 ~ p.11
|
|
|
An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database)
|
|
Mitchell E. Geffner
Michael B. Ranke
Michael P. Wajnrajch
|
|
|
Abstract
|
|
|
|
The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.
|
|
|
KEYWORD
|
|
|
Kabi International Growth Study, Pharmaco-epidemiological study, Recombinant human growth hormone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|